C

바이오솔루션

086820KOSDAQ기초 의약물질 제조업

44.8 / 100

Reference Date: 2026-06-10

Financial Score10.0 / 40
News Sentiment18.8 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Plunged 35.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

BioSolution is a biotech company specializing in the research, development, and commercialization of advanced biopharmaceuticals, human tissue models, and biofusion materials based on stem cell and tissue engineering technologies. Key products include Kerahil for burn treatment and Catilife for cancer therapy, with OECD and ISO certifications enabling entry into alternative toxicity testing markets. The company also leads the clean and vegan cosmetics market through biofusion materials derived from plant stem cells and natural substances.

Number of Employees

100people

Average Salary

57.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
623.64Industry Average 27.710.0Point

22.5x industry avg (risky)

PBR
5.56Industry Average 1.740.0Point

3.2x industry avg (risky)

ROE
0.86Industry Average -6.033.5Point

Well below industry avg

Debt Ratio
7.08Industry Average 6.622.0Point

Higher than industry avg (caution)

Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲10.7% (2-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲6.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -11.5% (improving, 3yr)

Detailed News Sentiment

8 totalPositive 6Neutral 2Negative 0Average Sentiment Score 75

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 6,860Won52-week high 12,95052-week low 6,860
1-month return0.0Point

1m -35.10% (strong drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral분기보고서 (2026.03)2026-05-15